Go to content

News

Filters

Changing any of the form inputs will cause the content to refresh with the filtered results.

Skip filters

Next Generation Lipid Nanoparticles for Clinical Development of mRNA-based Therapeutics

Dr. Ying Tam, Chief Scientific Officer

13th International mRNA Health Conference, Berlin, Germany

Read about Next Generation Lipid Nanoparticles for Clinical Development of mRNA-based Therapeutics

Effect of Body Weight and Anti-inflammatory Pre-medications and Concomitant Medications on the Pharmacodynamic Activity and Tolerability of mRNA-Lipid Nanoparticle Formulations in Monkeys 

Dr. Sherry Weppler, Sr. Research Scientist I
13th International mRNA Health Conference, Berlin, Germany

Read about Effect of Body Weight and Anti-inflammatory Pre-medications and Concomitant Medications on the Pharmacodynamic Activity and Tolerability of mRNA-Lipid Nanoparticle Formulations in Monkeys 

Novel Lipids with Improved Activity for Prophylactic Vaccine Development

Dr. Ghania Chikh, Sr. Director, Vaccine Development
10th International Conference on Vaccines Research & Development, Boston, MA
13th International mRNA Health Conference, Berlin, Germany

Read about Novel Lipids with Improved Activity for Prophylactic Vaccine Development

Development of mRNA-LNP for Cancer Vaccine

Dr. Fan Yan, Research Scientist II – 10th International Conference on Vaccines Research & Development, Boston, MA
Dr. Ghania Chikh, Sr. Director, Vaccine Development – 13th International mRNA Health Conference, Berlin, Germany

Read about Development of mRNA-LNP for Cancer Vaccine

An Alternative Method to RNA Lipid Nanoparticle Production

Mitchell Beattie, Research Scientist I
Controlled Release Society Annual Meeting & Exposition, Philadelphia, PA

Read about An Alternative Method to RNA Lipid Nanoparticle Production

Evolving Lipid Nanoparticles to Optimize Clinical Application of messenger RNA Therapeutics

Dr. Ying Tam, Chief Scientific Officer

TIDES USA, San Diego, CA

Read about Evolving Lipid Nanoparticles to Optimize Clinical Application of messenger RNA Therapeutics

Pharmacodynamic Activity, Pharmacokinetics and Tolerability of Lipid Nanoparticle Formulations of mRNA Following Repeated Intravenous Dosing in Monkeys 

Sean Semple, Vice President, Preclinical Research

American Society of Gene & Cell Therapy’s Annual General Meeting, New Orleans, LA

Read about Pharmacodynamic Activity, Pharmacokinetics and Tolerability of Lipid Nanoparticle Formulations of mRNA Following Repeated Intravenous Dosing in Monkeys 

Delivery, Potency, and Tolerability of Lipid Nanoparticle Formulations of mRNA in PXB-mice

Merete Eisenhardt, Senior Manager, Preclinical/Regulatory
American Society of Gene & Cell Therapy’s Annual General Meeting, New Orleans, LA

Read about Delivery, Potency, and Tolerability of Lipid Nanoparticle Formulations of mRNA in PXB-mice

Improved T Cell Delivery and Expression of mRNA Using CD8-Targeted Lipid Nanoparticles with Athebody® Designed Ankyrin Repeat Proteins (DARPins)

Dr. Ying Tam, Chief Scientific Officer

American Society of Gene & Cell Therapy’s Annual General Meeting, New Orleans, LA

Read about Improved T Cell Delivery and Expression of mRNA Using CD8-Targeted Lipid Nanoparticles with Athebody® Designed Ankyrin Repeat Proteins (DARPins)

Development of LNP for mRNA Cancer Immunotherapy (Presentation)

Dr. Ghania Chikh, Senior Director, Vaccine Development
World Vaccine Congress, Washington, DC

Read about Development of LNP for mRNA Cancer Immunotherapy (Presentation)

Development of LNP for mRNA Cancer Immunotherapy (Poster)

Dr. Ghania Chikh, Senior Director, Vaccine Development
World Vaccine Congress, Washington, DC

Read about Development of LNP for mRNA Cancer Immunotherapy (Poster)

Identification of Novel Lipids with Improved Activity for Prophylactic Vaccine Development

Dr. Thomas Chamberlain, Senior Research Scientist I
World Vaccine Congress, Washington, DC

Read about Identification of Novel Lipids with Improved Activity for Prophylactic Vaccine Development